Abstract:Background: Maximizing survival for patients with primary cutaneous melanomas (melanomas) depends on an early diagnosis and appropriate management. Several new drugs have been shown to improve survival in high-risk melanoma patients. Despite well-documented guidelines, many patients do not receive optimal management, particularly when considering patient age. Objective: to provide an update on melanoma management from the time of the decision to biopsy a suspicious skin lesion. Methods: We reviewed melanoma-management research published between 2018 and 2023 and identified where such findings impact and update the management of confirmed melanomas. Pubmed, Google Scholar, Ovid and Cochrane Library were used as search tools. Results: We identified 81 publications since 2017 that have changed melanoma management; 11 in 2018, 12 in 2019, 10 in 2020, 12 in 2021, 17 in 2022 and 18 in 2023. Discussion: Delayed or inaccurate diagnosis is more likely to occur when a partial shave or punch biopsy is used to obtain the histopathology. Wherever feasible, a local excision with a narrow margin should be the biopsy method of choice for a suspected melanoma. The Breslow thickness of the melanoma remains the single most important predictor of outcome, followed by patient age and then ulceration. The BAUSSS biomarker, (Breslow thickness, Age, Ulceration, Subtype, Sex and Site) provides a more accurate method of determining mortality risk than older currently employed approaches, including sentinel lymph node biopsy. Patients with metastatic melanomas and/or nodal disease should be considered for adjuvant drug therapy (ADT). Further, high-risk melanoma patients are increasingly considered for ADT, even without disease spread. Invasive melanomas less than 1 mm thick are usually managed with a radial excision margin of 10 mms of normal skin. If the thickness is 1 to 2 mm, select a radial margin of 10 to 20 mm. When the Breslow thickness is over 2 mm, a 20 mm clinical margin is usually undertaken. In situ melanomas are usually managed with a 5 to 10 mm margin or Mohs margin control surgery. Such wide excisions around a given melanoma is the only surgery that can be regarded as therapeutic and required. Patients who have had one melanoma are at increased risk of another melanoma. Ideal ongoing management includes regular lifelong skin checks. Total body photography should be considered if the patient has many naevi, especially when atypical/dysplastic naevi are identified. Targeted approaches to improve occupational or lifestyle exposure to ultraviolet light are important. Management also needs to include the consideration of vitamin D supplementary therapy.

Management of Localized Melanoma in the Anti-PD-1 Era

Primary Cutaneous Melanoma—Management in 2024

A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease

Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update

Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions

Therapeutic options in cutaneous melanoma: latest developments

Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma

The safety of anti PD-1 therapeutics for the treatment of melanoma

Changes in the surgical management of melanoma and measures to implement change

Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential

The current progress of PD-1 / PD-L1 mAb applications in melanoma immunotherapy

Management of acral lentiginous melanoma: current updates and future directions

Evidence for Radiation Therapy in Stage III Locoregionally Advanced Cutaneous Melanoma in the Post-Immunotherapy Era: A Literature Review

Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy

Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances

A Review of Current and Pipeline Drugs for Treatment of Melanoma

The Current State of Neoadjuvant Therapy in Resectable Advanced Stage Melanoma

Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials

Recent Advances in the Management of Malignant Melanoma

Advances in the discovery and development of melanoma drug therapies

Local and Systemic Management Options for Melanoma Brain Metastases